Handelsavisen
prelaunch
Companies ›Consumer Non Cyclicals ›MIST.BO
MI
MIST.BO — BSE (India) Food Processing

Mist.Bo

$4,46
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
24,6 %
ROE
34,7 %
Net margin
24,2 %
Debt / equity
0,05
Beta
—
52w range
—
Volume
2,3k
Day range
$1,41–$1,47
Prev close
$1,40
Open
$1,47
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

MIST.BO is a food processing company that generates revenue primarily through the production and sale of food products.

Business. Milestone Pharmaceuticals Inc (MIST.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Beverages
IndustryFood Processing
Generated · model-assisted
Sell-side consensus
BUY6 analysts
5 buy1 hold0 sell
Avg 12m price target6,50

Analyst recommendations

6 analysts · consensus Buy
Buy5
Hold1
Sell0
12-month price target
6,50
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
6 analysts · indicative
Ownership→
Goldman Sachs Asset Management, L.P.
largest disclosed fund holder
Profitability→
34,7 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning MIST.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to MIST.BO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Milestone Pharmaceuticals Inc (MIST.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorFood & Beverages
    IndustryFood Processing
    AI synthesis
    GENERATED

    MIST.BO exhibits a strong capital structure with a debt-to-equity ratio of 0.05, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 5.84, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's operating cash flow is negative at -486.51 million INR, which may raise concerns about its ability to fund operations from core business activities.

    In terms of profitability, MIST.BO demonstrates a return on equity (ROE) of 34.69% and a return on assets (ROA) of 28.19%, both of which are strong indicators of efficient use of equity and assets to generate profits. These figures suggest that the company is performing well relative to industry standards, although specific comparisons to cohort medians are not available in the provided data.

    The company's revenue is concentrated in the food processing segment, with no disclosed geographic diversification in the provided data. This concentration may expose the company to risks associated with market fluctuations in the food processing industry.

    MIST.BO's growth trajectory is not explicitly detailed in the provided data, but the company's strong ROE and ROA suggest a potential for continued profitability. The absence of specific growth metrics and outlooks for the current and next fiscal years limits the ability to assess future performance accurately.

    The risk assessment for MIST.BO indicates a medium liquidity risk and a low dilution risk. The company's key financial flag is the negative net cash position after subtracting total debt, which could impact its financial flexibility. The dilution potential is low, and no significant adjustments have been applied to the valuation metrics, indicating a stable capital structure.

    Recent events and filings for MIST.BO are not detailed in the provided data, which limits the ability to assess any recent developments that may impact the company's financial position or strategic direction.

    Key takeaways
    • MIST.BO has a strong return on equity (34.69%) and return on assets (28.19%), indicating efficient use of capital.
    • The company's debt-to-equity ratio is low at 0.05, suggesting a conservative capital structure.
    • MIST.BO's liquidity position is medium, with a current ratio of 5.84, but its operating cash flow is negative.
    • The company's revenue is concentrated in the food processing segment, with no disclosed geographic diversification.
    • The risk assessment indicates a medium liquidity risk and a low dilution risk.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $4,46
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $9.61B
    Net cashⓘ
    -$467.7M
    Current ratioⓘ
    5.8
    Debt / equityⓘ
    0.1
    ROAⓘ
    28.2%
    ROEⓘ
    34.7%
    Cash conversionⓘ
    -15.0%
    CapEx / revenueⓘ
    0.0%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,40
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    6
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-22 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$2,00
    Mean$6,50
    Median$7,50
    High$8,00
    Spot$4,46
    +45.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin24,6 %Best in class
    Net Margin24,2 %Best in class
    ROE34,7 %Best in class
    Capex / Rev0,0 %Above P75
    D/E0,05Above median
    Cash Conv-0,15Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 3 564 000 sh5 exercises · 22 grants12 insiders
    • Fischer Seth H. Z.Director · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
    • Wills Robert JamesDirector · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
    • TOMSICEK MICHAEL JOHNDirector · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
    • Saik AndrewDirector · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
    • PAPA JOSEPH CDirector · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
    • Giles Lisa M.Director · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
    • Duty StuartDirector · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
    • Muller LorenzChief Commercial Officer · Employee Stock Option (right to buy) → Common SharesAcquired 204 000 @ $1,97grant · 2026-02-02
    • Bharucha DavidChief Medical Officer · Restricted Stock Unit → Common SharesAcquired 136 000grant · 2026-02-02
    • Oliveto JosephDirector, President and CEO · Restricted Stock Unit → Common SharesAcquired 453 000grant · 2026-02-02
    • Oliveto JosephDirector, President and CEO · Employee Stock Option (right to buy) → Common SharesAcquired 679 000 @ $1,97grant · 2026-02-02
    • Bharucha DavidChief Medical Officer · Employee Stock Option (right to buy) → Common SharesAcquired 204 000 @ $1,97grant · 2026-02-02
    • Nelson Jeffrey EdwardChief Operating Officer · Restricted Stock Unit → Common SharesAcquired 136 000grant · 2026-02-02
    • Nelson Jeffrey EdwardChief Operating Officer · Employee Stock Option (right to buy) → Common SharesAcquired 204 000 @ $1,97grant · 2026-02-02
    • Hasija AmitCFO & EVP of Corp. Development · Restricted Stock Unit → Common SharesAcquired 136 000grant · 2026-02-02
    • Hasija AmitCFO & EVP of Corp. Development · Employee Stock Option (right to buy) → Common SharesAcquired 204 000 @ $1,97grant · 2026-02-02
    • Muller LorenzChief Commercial Officer · Restricted Stock Unit → Common SharesAcquired 136 000grant · 2026-02-02
    • Bharucha DavidChief Medical Officer · Restricted Stock Units → Common SharesDisposed 20 100exercise · 2026-01-26
    • Muller LorenzChief Commercial Officer · Restricted Stock Units → Common SharesDisposed 20 100exercise · 2026-01-26
    • Oliveto JosephDirector, President and CEO · Restricted Stock Units → Common SharesDisposed 66 600exercise · 2026-01-26
    • Hasija AmitCFO & EVP of Corp. Development · Restricted Stock Units → Common SharesDisposed 20 100exercise · 2026-01-26
    • Nelson Jeffrey EdwardChief Operating Officer · Restricted Stock Units → Common SharesDisposed 20 100exercise · 2026-01-26
    • Bharucha DavidChief Medical Officer · Employee Stock Option (right to buy) → Common SharesAcquired 100 000 @ $1,74grant · 2025-12-12
    • Nelson Jeffrey EdwardChief Operating Officer · Employee Stock Option (right to buy) → Common SharesAcquired 100 000 @ $1,74grant · 2025-12-12
    • Muller LorenzChief Commercial Officer · Employee Stock Option (right to buy) → Common SharesAcquired 100 000 @ $1,74grant · 2025-12-12

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • MIST.BO Market data — financials · 2026-05-28

    Ownership & reference

    Top holders

    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$2M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$7M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Joseph OlivetoPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 13 sellsnet -$1,2M5 insiders · last 365d
    • Oliveto JosephDirector, President and CEO · Common SharesSold 36 500 @ $2,26$82K · 2026-04-16
    • Muller LorenzChief Commercial Officer · Common SharesSold 11 180 @ $1,93$22K · 2026-01-26
    • Muller LorenzChief Commercial Officer · Common SharesOther 20 100 · 2026-01-26
    • Bharucha DavidChief Medical Officer · Common SharesOther 20 100 · 2026-01-26
    • Bharucha DavidChief Medical Officer · Common SharesSold 12 245 @ $1,93$24K · 2026-01-26
    • Oliveto JosephDirector, President and CEO · Common SharesSold 34 523 @ $1,93$67K · 2026-01-26
    • Oliveto JosephDirector, President and CEO · Common SharesOther 66 600 · 2026-01-26
    • Nelson Jeffrey EdwardChief Operating Officer · Common SharesOther 20 100 · 2026-01-26
    • Nelson Jeffrey EdwardChief Operating Officer · Common SharesSold 12 245 @ $1,93$24K · 2026-01-26
    • Hasija AmitCFO & EVP of Corp. Development · Common SharesSold 12 245 @ $1,93$24K · 2026-01-26
    • Hasija AmitCFO & EVP of Corp. Development · Common SharesOther 20 100 · 2026-01-26
    • Oliveto JosephDirector, President and CEO · Common SharesSold 43 000 @ $2,25$97K · 2026-01-08
    • Oliveto JosephDirector, President and CEO · Common SharesSold 500 @ $2,25$1K · 2026-01-07
    • Oliveto JosephDirector, President and CEO · Common SharesSold 133 054 @ $2,32$309K · 2025-12-15
    • Nelson Jeffrey EdwardChief Operating Officer · Common SharesSold 58 007 @ $2,32$135K · 2025-12-15
    • Hasija AmitCFO & EVP of Corp. Development · Common SharesSold 58 007 @ $2,32$135K · 2025-12-15
    • Bharucha DavidChief Medical Officer · Common SharesSold 58 007 @ $2,32$135K · 2025-12-15
    • Muller LorenzChief Commercial Officer · Common SharesSold 53 566 @ $2,32$124K · 2025-12-15
    • Hasija AmitCFO & EVP of Corp. Development · Common SharesOther 100 000 · 2025-12-12
    • Muller LorenzChief Commercial Officer · Common SharesOther 100 000 · 2025-12-12
    • Oliveto JosephDirector, President and CEO · Common SharesOther 280 000 · 2025-12-12
    • Nelson Jeffrey EdwardChief Operating Officer · Common SharesOther 100 000 · 2025-12-12
    • Bharucha DavidChief Medical Officer · Common SharesOther 100 000 · 2025-12-12
    • Muller LorenzChief Commercial Officer · Common SharesOther 25 000 · 2025-12-09

    Short positioning

    14.6Mshares short+15.8% vs prior
    13.59days to cover
    51.7%short of daily vol
    83.6Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    MIST.BOCanonical
    BSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 217.7%Derived (calculated)
    • Return on equity (FY 2025-12-31): -0.2%Derived (calculated)
    • Return on assets (FY 2025-12-31): -0.1%Derived (calculated)
    • Current ratio (FY 2025-12-31): 8.01xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.72xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 815.2%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 188.6%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -11.9%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -11.9%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -51.9%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -70.0%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -47.6%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 26.1%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 15.1%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 7.2%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 50.4%Derived (calculated)
    • Operating cash flow (annual): USD -49.04MSEC XBRL filing
    • Current liabilities (annual): USD 13.98MSEC XBRL filing
    • Total liabilities (annual): USD 71.79MSEC XBRL filing
    • Total assets (annual): USD 113.56MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
    • R&D expense (annual): USD 18.11MSEC XBRL filing
    • Operating income (annual): USD -62.14MSEC XBRL filing
    • Long-term debt (annual): USD 57.19MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-15FILINGFORM 8-K →
    2026-06-10 00:00 UTCINSIDER7 insider transactions — 2026-06 7 derivative
    2026-06-10INSIDERPAPA JOSEPH C acquired 77.0k sh Stock Option (right to buy) — Director
    2026-06-10INSIDERSaik Andrew acquired 77.0k sh Stock Option (right to buy) — Director
    2026-06-10INSIDERTOMSICEK MICHAEL JOHN acquired 77.0k sh Stock Option (right to buy) — Director
    2026-06-10INSIDERDuty Stuart acquired 77.0k sh Stock Option (right to buy) — Director
    2026-06-10INSIDERWills Robert James acquired 77.0k sh Stock Option (right to buy) — Director
    2026-06-10INSIDERGiles Lisa M. acquired 77.0k sh Stock Option (right to buy) — Director
    2026-06-10INSIDERFischer Seth H. Z. acquired 77.0k sh Stock Option (right to buy) — Director
    2026-05-13FILINGFORM 8-K →
    2026-05-13FILING10-Q filing →
    2026-04-30FILINGFORM DEF 14A →
    2026-04-16 00:00 UTCINSIDER1 insider transaction — 2026-04
    2026-04-16INSIDEROliveto Joseph sold 36.5k sh Common Shares — Director, President and CEO ~$82k
    2026-03-20FILINGFORM 8-K →
    2026-03-20FILING10-K filing →
    2026-02-02 00:00 UTCINSIDER10 insider transactions — 2026-02 10 derivative
    2026-02-02INSIDERMuller Lorenz acquired 204.0k sh Employee Stock Option (right to buy) — Chief Commercial Officer
    2026-02-02INSIDERBharucha David acquired 136.0k sh Restricted Stock Unit — Chief Medical Officer
    2026-02-02INSIDEROliveto Joseph acquired 679.0k sh Employee Stock Option (right to buy) — Director, President and CEO
    2026-02-02INSIDEROliveto Joseph acquired 453.0k sh Restricted Stock Unit — Director, President and CEO
    2026-02-02INSIDERHasija Amit acquired 204.0k sh Employee Stock Option (right to buy) — CFO & EVP of Corp. Development
    2026-02-02INSIDERHasija Amit acquired 136.0k sh Restricted Stock Unit — CFO & EVP of Corp. Development
    2026-02-02INSIDERNelson Jeffrey Edward acquired 204.0k sh Employee Stock Option (right to buy) — Chief Operating Officer
    2026-02-02INSIDERNelson Jeffrey Edward acquired 136.0k sh Restricted Stock Unit — Chief Operating Officer
    2026-02-02INSIDERBharucha David acquired 204.0k sh Employee Stock Option (right to buy) — Chief Medical Officer
    2026-02-02INSIDERMuller Lorenz acquired 136.0k sh Restricted Stock Unit — Chief Commercial Officer
    2026-01-26 00:00 UTCINSIDER17 insider transactions — 2026-01 · net sell $257k 5 derivative
    2026-01-26FILINGFORM 8-K →
    2026-01-26INSIDERMuller Lorenz sold 11.2k sh Common Shares — Chief Commercial Officer ~$22k
    2026-01-26INSIDERMuller Lorenz transacted 20.1k sh Common Shares — Chief Commercial Officer
    2026-01-26INSIDERBharucha David transacted 20.1k sh Common Shares — Chief Medical Officer
    2026-01-26INSIDERBharucha David sold 12.2k sh Common Shares — Chief Medical Officer ~$24k
    2026-01-26INSIDEROliveto Joseph sold 34.5k sh Common Shares — Director, President and CEO ~$67k
    2026-01-26INSIDEROliveto Joseph transacted 66.6k sh Common Shares — Director, President and CEO
    2026-01-26INSIDERNelson Jeffrey Edward transacted 20.1k sh Common Shares — Chief Operating Officer
    2026-01-26INSIDERNelson Jeffrey Edward sold 12.2k sh Common Shares — Chief Operating Officer ~$24k
    2026-01-26INSIDERHasija Amit sold 12.2k sh Common Shares — CFO & EVP of Corp. Development ~$24k
    Showing the 40 most recent of 60 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage